1332075-40-7

• 常用中文名：Tirofiban-d9
• 常用英文名：Tirofiban-d9
• CAS号：1332075-40-7
• 分子式：C₂₂H₂₇D₉N₂O₅S
• 分子量：449.65
• 相关类别： 信号通路 细胞骨架 Integrin
• 发布时间：2022-06-16 09:51:13
• 更新时间：2024-04-05 21:26:16
• 替罗非班-d9是氘标记的替罗非班。

名称

• 英文名: Tirofiban-d9

物化性质

• 分子式: C₂₂H₂₇D₉N₂O₅S
• 分子量: 449.65

生物活性

• 描述: 替罗非班-d9是氘标记的替罗非班。
• 相关类别:
  研究领域 >> 心血管疾病
  信号通路 >> 细胞骨架 >> Integrin
• 体外研究: 氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
• 参考文献:

  [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

  [2]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46.

  [3]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100.

  [4]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49.

  [5]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19.

  [6]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53.